VivoSeq
Cardiovascular

Peripheral Artery Disease

35

Pipeline Programs↗

9

Active Trials↗

19

Companies Involved↗

Peripheral Artery Disease is a moderately active landscape with 35 programs across 19 companies. The most active players are Proteon Therapeutics, Arog Pharmaceuticals, Inc., Biogen. 8 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

70/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Proteon Therapeutics

2 programs

Phase 1A

Arog Pharmaceuticals, Inc.

1 program

Phase 1Biogen logo

Biogen

1 program

Phase 1Z

Zhejiang Genfleet Therapeutics Co., Ltd.

1 program

Phase 2J

Juventas Therapeutics, Inc.

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

34 of 37 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody13%Protein / enzyme13%Peptide13%

Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 43 pipeline programs.

Analysis

Trial Status

45

clinical trials

Completed21 · 47%
Recruiting8 · 18%
Unknown status6 · 13%
Terminated5 · 11%
Withdrawn4 · 9%
Active, not recruiting1 · 2%

Clinical Trials

Trial Activity

45 trials

Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease
Recruiting·UUniversity of Pennsylvania·Phase 1·NCT06212271·24 enrolled
Improving Mobility After Revascularization in Peripheral Artery Disease
Recruiting·NNorthwestern University·Phase 3·NCT06686121·386 enrolled
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Recruiting·PPopulation Health Research Institute·Phase 3·NCT04774159·6,150 enrolled
Campania Registry On Peripheral Artery Disease
Recruiting·FFederico II University·N/A·NCT04903912·1,000 enrolled
Red Light Treatment in Peripheral Artery Disease
Recruiting·UUniversity of Alabama at Birmingham·N/A·NCT03203239·40 enrolled
Prospective Observational Cohort Study on the Prevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease
Recruiting·CCentre Hospitalier Intercommunal de Toulon La Seyne sur Mer·N/A·NCT07283289·295 enrolled
Effectiveness of a Home-based Cardiovascular Rehabilitation Program Compared With Standard Care in Patients With Moderate to Severe Peripheral Artery Disease: a Pilot Randomized Controlled Trial (PILOT-PAD-CYCLE)
Recruiting·LLaval University·Preclinical·NCT07655206·12 enrolled
Impact of Nrf2 Activation on Macrovascular Function, Microvascular Function, Leg Function, and Walking Capacity in Patients With Peripheral Artery Disease
Recruiting·UUniversity of Nebraska·Phase 1·NCT06319339·20 enrolled
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
Active, not recruiting·VVanderbilt University Medical Center·Phase 4·NCT05009862·75 enrolled
Treadmill Exercise and GM-CSF Study to Improving Functioning in Peripheral Artery Disease (PAD)
Completed·NNorthwestern University·N/A·NCT01408901·210 enrolled
Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease
Completed·NNorthwestern University·N/A·NCT02593110·114 enrolled
DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease
Completed·RRadboud University Medical Center·Phase 4·NCT04218656·159 enrolled
Autologous Angiogenic Cell Precursors (ACPs) for the Treatment of Peripheral Artery Disease
Completed·SSalus Ltd.·Phase 2·NCT01584986·22 enrolled
Comparison Study of Vasovist® Magnetic Resonance Angiography (MRA) and an MRA With a Conventional Extracellular Contrast Agent With X-ray Angiography in Patients With Peripheral Artery Disease
Completed·Bayer logoBayer·Phase 3·NCT00296855·261 enrolled
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT01732822·13,885 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)